Is A Late Stage Ovarian Cancer Patient Alive 19 Years Later Because Of Serendipity

A late stage German ovarian cancer patient, who was given months to live, in 1987 was injected with a then-experimental bio tech drug. The monoclonal antibody was being used to track tumors in the ovarian cancer patients body. Instead, it may lead to a breakthrough treatment for ovarian cancer patients.

In a recent internet news website article, University of Alberta Professor Emeritus Antoine Noujaim told, ?There is the very original (ovarian cancer) patient who was injected in 1987. She?s in Germany, and according to Dr. Baum she was still alive a year ago.? Over 500 patients were injected with the murine monoclonal antibody, which Dr. Antoine Noujaim pioneered during early clinical trials, to determine the ovarian cancer drug?s efficacy. The ovarian cancer drug came about by accident when Dr. Baum, a researcher in Germany noticed an improvement in late stage ovarian cancer patients. He was using the ?B43.13 antibody,? which Dr. Noujaim had developed for imaging tumors in women with late stage ovarian cancer. Dr. Baum became puzzled when they were not dying on schedule, and notified Dr. Noujaim who began his two-decade long quest to commercialize the discovery.

As a result of this nearly twenty-year old scientific accident, one such German patient may very well be alive today. According to Dr. Noujaim, who told, ?It?s a matter of great pride for me that some people who received OvaRex? MAb are alive today.? The murine monoclonal antibody is reportedly designed to help the patient?s immune system recognize and more effectively fight ovarian cancer. Previous clinical studies showed an ?average time to relapse? of 14 months.

Phase III clinical trials for OvaRex? MAb are currently being conducted in about 64 research centers across the United States through Unither Pharmaceuticals, a wholly owned subsidiary of United Therapeutics (NASDAQ NM: UTHR), which has licensed OvaRex? MAb, from ViRexx Medical Corp (Amex: REX; Toronto: VIR).

The interview with OvaRex? MAb inventor, Dr. Antoine Noujaim can be found on the internet news website,


Contact Details

Company Name: ArtJen Complexus Holding s Corp.
Issued By: Joseph Artiss
Website: Visit the website

by Joseph Artiss (few years ago!)

Latest Press Releases

The Mad Hatter Now Offer a Full Line of Hearth Products and Full Line of Grills

Diabetes Insulin Delivery Pens Market Research Report 2018

Dr Kapadia Provides Tips to Patients Interested in Hair Transplant Procedures

love vashikaran specialist

Solar Blanket Sales Market Report 2018

Spring Bottled Water Market Insights, Forecast to 2025

Biochemical Incubator Sales Market Report 2018

Quinine Sulphate Sales Market Report 2018

Automotive Chassisc System Market Insights, Forecast to 2025

2,6-Dicarboxypyridine market size in key regions like North America, Europe, Asia Pacific an..

Remove this press release ?

Due to extra work required to remove the press-releases we have started charging $1.99 for press release removal.

Your press release will be removed in 24 hours, once the payment has been received.

Search Press Release
e.g. Business, Computer, etc.